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Stroke 
• Atrial fibrillation (afib) is the most 
common sustained cardiac 
arrhythmia and second most 
common cardiovascular condition 
in adults in the United States 
(Zarraga & Kron, 2012). 
• 2.2 million affected, increases risk 
of stroke 4 to 6 times (National 
Institute of Neurological Disorders 
and Stroke [NINDS], 2015).  
• Vitamin K antagonists (VKAs) have 
been mainstay of therapy for over 
60 years (King, Holley& Moores, 
2013). 
• Limitations with VKAs such as 
variability in response, need for 
frequent lab draws, food and drug 
interactions which decrease 
patients adherence and under 
prescribing by physicians (Halperin 
& Goyette, 2012).  
• Novel oral anticoagulants (NOACs) 
have been approved by FDA over 
last 5 years for management  of 
non-valvular afib and stroke 
prevention.  
• Non-valvular afib is afib in the 
absence of rheumatic mitral 
stenosis, a mechanical or 
bioprosthetic heart valve, or mitral 
valve repair (Koza, 2014). 
• NOACs are direct thrombin 
inhibitors and Xa inhibitors that 
intend to improve patient 
adherence, simplify anticoagulation, 
and overcome barriers to long term 
therapy. 
• Important to know what population 
is appropriate, what are bleeding 
risks, reversal agents, cost, overall 
benefit to NOACs versus VKAs.  
• Blood supply is interrupted or reduced and oxygen and nutrients cannot get 
to brain tissue, leading to brain cell death. 
• Two types are ischemic and hemorrhagic. 
• Ischemic stroke include transient ischemic attacks (TIAs) which are temporary 
blockage that does not leave permanent symptoms (NIH, 2014). 
• Ischemic stroke from plaque build up and rupture in arteries, leading to 
clotting cascade, completely or partially blocking artery (NIH, 2014). 
• Embolic stroke is a type of ischemic stroke that is caused either from plaque 
breaking off of an artery and goes to artery in the brain, or from a blood clot 
that goes to an artery in the brain (NIH, 2014). 
• Hemorrhagic stroke occurs due to increase pressure on the walls of the 
arteries of the brain. 
• High blood pressure, aneurysms, arteriovenous malformations (AVMs) are all 
causes of hemorrhagic strokes (NIH, 2014).  
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• Important to know the pathophysiology of afib and stroke to understand why 
anticoagulation is needed. 
• Non-valvular afib independently increases the risk of embolic stroke five fold 
(Deedwania & Huang, 2011).  
• Risk of ischemic stroke and systemic embolism increases 4-5% per year without 
thromboprophylaxis (Halperin & Goyette, 2012).  
• Specifically for non-valvular afib, two categories of anticoagulants can be used, 
VKAs, and NOACs.  
• In relation to clot formation from the pathophysiology of afib and stroke, health 
care provider should understand how each medication works in the coagulation 
cascade. 
VKAs 
• VKAs such as warfarin, interrupt the conversion of vitamin K, which then inhibits 
the formation of vitamin K-dependent clotting factors in the coagulation cascade 
(Ogbonna & Jeffery , 2013).  
• Coagulation factors II, VII, IX, and X are vitamin K-dependent proteins in the 
coagulation cascade. 
• Interruption of the clotting factors prevents conversion of VII, IX, and X to factor Xa, 
and factor II ((prothrombin) to factor IIa (thrombin). 
NOACs 
• Most studied are factor Xa inhibitors, rivaroxaban and apixaban, and direct 
thrombin inhibitor, dabigatran.  
• Factor Xa and cofactor Va form prothrombinase complex that activates 
prothrombin to thrombin, which is a major part of clotting process (King, Holley 
&Moores, 2013). 
• Thrombin converts fibrinogen to fibrin, as well as other factors that lead to further 
strengthening of the clot. 
• Thrombin has three sites it can be bound. Heparin requires binding to all three 
sites to inactivate thrombin, therefore bound thrombin is not effected by heparin 
(King, Holley & Moores, 2013).  
• Direct thrombin inhibitors bind directly to thrombin, and inhibit both soluble and 
clot bound thrombin, and factor Xa inhibitors  can act on both free and clot-bound 
factor Xa (King, Holley & Moores). 
• Have ability to improve accuracy of treatment for afib and stroke.  
 
Significance of Pathophysiology 
• Non-valvular afib increases in 
prevalence with age and often requires 
the use of oral anticoagulants to prevent 
ischemic stroke (Halperin & Goyette, 
2012). 
• Will likely see many patients with non-
valvular afib and stroke and need 
evidence based knowledge to decide 
between VKAs and NOACs. 
• CHA2DS2-VASc is newest index to 
determine risk for stroke with afib.  
• The higher the individuals score, the 
higher the chance of thromboembolic 
events (Zarraga & Kron, 2013). 
Direct Thrombin Inhibitor-Dabigatran 
• Dabigatran study showed 32% less 
likely to have ischemic stroke, systemic 
embolism, hemorrhagic stroke and acute 
myocardial infarction, no relation 
between dabigatran and harm outcomes 
except for gastrointestinal (GI) bleeding 
(Lauffenburger, Farley, Gehi, Rhoney, 
Brookhart, & Fang, 2015). 
• Study used a large database of 
participants in real world practice, 2 
years after dabigatran became available. 
• Precaution and dose adjustment for 
renal impairment and elderly at 
increased risk for GI tract bleeding 
(Adam, McDuffie, Ortel, & Williams, 
2012).  
• Stopped more often than other NOACs 
due to adverse side effects in GI system 
(Adam et al., 2012).  
Factor Xa inhibitors (rivaroxaban and 
apixaban) 
• Rivaroxaban found to be non-inferior  to 
VKA warfarin for prevention of stroke or 
systemic embolism but was found to 
have less intracranial and fatal bleeding 
(Ogbonna & Jeffery, 2013). 
• Apixaban found to be superior to VKA 
warfarin in prevention of stroke or 
systemic embolism as well as lower 
rates of bleeding complications 
(Ogbonna & Jeffery, 2013). 
Endoxaban 
• Newest direct factor Xa inhibitor being 
studied for non-valvular afib and stroke 
prevention. 
• Found to be non-inferior to VKA 
warfarin in reducing the rate of stroke 
and systemic embolism, with a  lower 
incidence of bleeding complications and 
cardiovascular deaths (Acharya & 
Deedwania, 2015). 
Atrial fibrillation: 
• Obvious for some, asymptomatic in 
others, difficult to diagnose 
• Palpitations, shortness of breath, 
weakness, exercise intolerance, chest 
pain, dizziness or fainting, fatigue, 
and confusion (National Heart. Lung 
and Blood Institute [NIH], 2014a).   
Stroke: 
• Major complication of afib is stroke. 
• Numbness, tingling in face, arm, or 
leg, especially on one side of body, 
weakness, confusion, difficulty 
speaking or understanding speech, 
trouble seeing, walking, loss of 
balance, dizziness, and lack of 
coordination (NIH, 2014b).  
Signs and Symptoms 
Atrial Fibrillation 
Normal conduction of the heart: 
 
• Begins with electrical signal from sinoatrial (SA) node in the right atrium, 
spreads signal across right and left atria, causing blood filled atria to contract 
and fill both ventricles  (NIH, 2011). 
• Electrical signal pauses at atrioventricular (AV) node to allow ventricles to 
continue filling, then travels down bundle of His to purkinje fibers causing 
ventricles to contract and force blood out to body and lungs (NIH, 2011). 
• Continual process at a consistent and steady rate. 
 
Atrial Fibrillation: 
 
• Cardiac cells have ability to self-stimulate as a protective mechanism in case 
heart’s conduction systems were to fail. 
• Multiple atrial cells begin self-stimulating and compete with SA node, 
eventually taking over causing rapid, irregular beats, and ineffective 
contractions (Koza, 2014).  
• Over self-stimulation of atrial cells due to structural heart defects from heart 
disease associated with hypertension, coronary artery disease, heart failure, 
valvular heart disease, and cardiomyopathies, causes increased atrial 
pressures, atrial dilation, altered wall stress (Koza, 2014). 
• Atria quiver and lose atrial kick (effective contraction from atria). 
• Blood pooling and stasis occur, commonly in left atrial appendage (LAA), 
leading to thrombi formation (Koza, 2014).  
• Thrombi can become dislodged causing stroke and other systemic 
thromboembolic. 
• Types of afib are paroxysmal (less than 7 days), persistent (greater than 7 
days,), long-standing persistent (greater than 12 months), permanent 
(determined by physician and patient to cease attempts at normal sinus 
rhythm), and non-valvular (discussed prior ) (Koza, 2014). 
The coagulation cascade and basic mechanisms of action of NOACs (King, Holley & 
Moores, 2013). 
• NOACs more viable option for long-term anticoagulation due to more 
predictable results, fewer drug interactions, and equal or better mortality and 
vascular outcomes in comparison to VKA warfarin (Adam et al, 2012).  
• Fixed, consistent dose, no lab draws, little food and drug interaction increase 
chance of adherence by patient. 
• Cost and reversal agent remains an issue yet to be completely fixed and studied. 
• NOACs are on the way to becoming the new mainstay of treatment of non-
valvular afib and stroke.  
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